Coastal Bridge Advisors LLC Makes New Investment in Stryker Corporation $SYK

Coastal Bridge Advisors LLC purchased a new stake in shares of Stryker Corporation (NYSE:SYK) during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 2,573 shares of the medical technology company’s stock, valued at approximately $810,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Brighton Jones LLC increased its holdings in shares of Stryker by 15.4% in the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock valued at $1,643,000 after purchasing an additional 609 shares during the period. Schnieders Capital Management LLC. acquired a new stake in shares of Stryker during the second quarter worth about $205,000. Marshall Wace LLP boosted its position in Stryker by 107.9% in the second quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company’s stock valued at $2,255,000 after buying an additional 77,831 shares during the last quarter. Nebula Research & Development LLC acquired a new position in Stryker in the 2nd quarter worth approximately $219,000. Finally, HUB Investment Partners LLC acquired a new position in Stryker in the 2nd quarter worth approximately $253,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Price Performance

Shares of NYSE SYK opened at $322.20 on Friday. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. The stock has a market capitalization of $123.58 billion, a price-to-earnings ratio of 33.39, a PEG ratio of 2.10 and a beta of 0.76. The firm’s 50 day simple moving average is $328.64 and its 200-day simple moving average is $331.47. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $396.86.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. The firm had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The firm’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Analysts expect that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s dividend payout ratio is presently 36.48%.

Analyst Ratings Changes

SYK has been the subject of several research reports. Piper Sandler decreased their price objective on shares of Stryker from $420.00 to $390.00 and set an “overweight” rating for the company in a research note on Friday, July 31st. BMO Capital Markets began coverage on shares of Stryker in a research note on Wednesday, July 8th. They issued an “outperform” rating and a $369.00 price objective on the stock. Wolfe Research downgraded shares of Stryker from an “outperform” rating to a “peer perform” rating in a research report on Thursday, August 13th. Needham & Company LLC lowered their price target on shares of Stryker from $454.00 to $418.00 and set a “buy” rating on the stock in a report on Friday, May 1st. Finally, BTIG Research cut their price target on Stryker from $371.00 to $358.00 and set a “buy” rating on the stock in a research report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $386.28.

Insider Activity at Stryker

In related news, insider Debra King sold 826 shares of the company’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total value of $277,783.80. Following the completion of the transaction, the insider owned 6,210 shares of the company’s stock, valued at approximately $2,088,423. This represents a 11.74% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Ronda E. Stryker sold 300,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $335.90, for a total value of $100,770,000.00. Following the completion of the sale, the director directly owned 2,301,375 shares in the company, valued at approximately $773,031,862.50. The trade was a 11.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 351,267 shares of company stock worth $118,197,701 in the last 90 days. Corporate insiders own 4.60% of the company’s stock.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.